Literature DB >> 28365829

Newcastle disease virus-like particles induce dendritic cell maturation and enhance viral-specific immune response.

Jing Qian1,2, Jiaxin Ding1,2, Renfu Yin1,2, Yixue Sun3, Cong Xue1,2, Xiaohong Xu1,2, Jianzhong Wang3, Chan Ding4, Shengqing Yu4, Xiufan Liu5, Shunlin Hu5, Yanlong Cong6,7, Zhuang Ding8,9.   

Abstract

Circulating of genotype VII Newcastle disease virus (NDV) is a great threat to the poultry industry worldwide. Virus-like particles (VLPs) are increasingly being considered as potential viral vaccines due to their safety and efficacy. In this study, we analyzed in vitro the stimulatory effects of VLPs containing the matrix and hemagglutinin-neuraminidase of genotype VII NDV on dendritic cells (DCs) and evaluated their immunogenicity in mice. The results showed that immature bone marrow-derived dendritic cells (BMDCs) responded to stimulation with VLPs by up-regulating expressions of MHC II, CD40, CD80, and CD86 molecules and by increasing the cytokine secretions of TNF-α, IFN-γ, IL-6, and IL-12p70. Besides, VLPs enhanced the immunostimulatory capacity of DCs to stimulate autologous T cell proliferation. Furthermore, VLPs can induce efficient humoral and cellular immune responses, and recruit mature DCs to the spleen in C57BL/6 mice, as shown by an obvious increase in double-positive proliferation of splenic CD11c+CD86+ cells. These data indicate that NDV VLPs can be a valuable candidate for NDV vaccine development.

Entities:  

Keywords:  Dendritic cell; Immune response; Newcastle disease virus; Virus-like particle

Mesh:

Substances:

Year:  2017        PMID: 28365829     DOI: 10.1007/s11262-017-1451-1

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  32 in total

1.  Dendritic cells: immunobiology and cancer immunotherapy.

Authors:  Carlos Ardavín; Sebastián Amigorena; Caetano Reis e Sousa
Journal:  Immunity       Date:  2004-01       Impact factor: 31.745

Review 2.  Virus-like particles as immunogens.

Authors:  Rob Noad; Polly Roy
Journal:  Trends Microbiol       Date:  2003-09       Impact factor: 17.079

Review 3.  Virus-like particles in vaccine development.

Authors:  António Roldão; Maria Candida M Mellado; Leda R Castilho; Manuel J T Carrondo; Paula M Alves
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

4.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

5.  Requirements for the assembly and release of Newcastle disease virus-like particles.

Authors:  Homer D Pantua; Lori W McGinnes; Mark E Peeples; Trudy G Morrison
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 6.  The coming of age of virus-like particle vaccines.

Authors:  Gary T Jennings; Martin F Bachmann
Journal:  Biol Chem       Date:  2008-05       Impact factor: 3.915

7.  Antigenic variation between Newcastle disease viruses of goose and chicken origin.

Authors:  Zhi-jie Li; Yang Li; Shuang Chang; Zhuang Ding; Lian-zhi Mu; Yan-long Cong
Journal:  Arch Virol       Date:  2010-03-05       Impact factor: 2.574

8.  Generation and characterization of chicken bone marrow-derived dendritic cells.

Authors:  Zhiguang Wu; Lisa Rothwell; John R Young; Jim Kaufman; Colin Butter; Pete Kaiser
Journal:  Immunology       Date:  2009-05-15       Impact factor: 7.397

9.  Evaluation of histopathological changes, viral load and immune function of domestic geese infected with Newcastle disease virus.

Authors:  Ailing Lu; Youxiang Diao; Hao Chen; Jiao Wang; Pingping Ge; Xiaoyan Sun; Dongmin Hao
Journal:  Avian Pathol       Date:  2014-07-09       Impact factor: 3.378

Review 10.  Myeloid C-type lectins in innate immunity.

Authors:  Matthew J Robinson; David Sancho; Emma C Slack; Salomé LeibundGut-Landmann; Caetano Reis e Sousa
Journal:  Nat Immunol       Date:  2006-12       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.